Condition

Non-Hodgkin's Lymphoma clinical trials and research

• 23Clinical trials
• 1New in 30 days
• 24Countries

Newest Non-Hodgkin's Lymphoma clinical trials

All recruiting trials (23)

• BEX101 CAR-T at the bedside for relapsed or refractory B-cell NHL

  A bedside, on-site CAR-T therapy called BEX101 is being tested in adults with relapsed or refractory B-cell non-Hodgkin’s lymphoma to see if it is safe and can help control the disease.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07882641

• KSVCBD Injection for B-cell Non-Hodgkin's Lymphoma with CD19 and/or BCMA

  This study tests KSVCBD, a CAR-T therapy made inside the body, in adults with relapsed or refractory B-cell non-Hodgkin's lymphoma to see if it is safe and can help fight the cancer.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07620314

• Comparing antibiotics and immunoglobulin to prevent infections in blood cancers

  This project tests whether immunoglobulin or antibiotic strategies better prevent infections in adults with blood cancers.

  Recruiting at 3 sites Phase 2/3 Monash University · Adelaide, South Australia and 2 other locations · NCT07202052

• Comparing two chemotherapy regimens for stem cell mobilization in lymphoma patients

  This study is testing a new combination of chemotherapy drugs to see if it helps lymphoma patients collect enough stem cells for treatment better than the standard approach.

  Recruiting at 17 sites Phase 3 The Affiliated People's Hospital of Ningbo University · Dongyang, Zhejiang and 16 other locations · NCT06520163

• T-Cell Therapy for Adults with Relapsed B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new T-cell therapy to see if it can help adults with relapsed B-cell non-Hodgkin's lymphoma feel better.

  Recruiting at 5 sites Phase 1/2 Estrella Immunopharma, Inc. · Sacramento, California and 4 other locations · NCT06343311

• CLIC-2201 treatment for relapsed B cell cancers

  This study is testing a new CAR-T cell therapy called CLIC-2201 to see if it can help people with relapsed B cell cancers feel better and improve their treatment outcomes.

  Recruiting at 7 sites Phase 1 British Columbia Cancer Agency · Calgary, Alberta and 6 other locations · NCT06208735

• Testing GNC-035 for patients with relapsed or refractory Non-Hodgkin's Lymphoma

  This study is testing a new treatment called GNC-035 to see if it can help people with relapsed or hard-to-treat Non-Hodgkin's Lymphoma feel better.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06066203

• Allogeneic CAR-T cell therapy for relapsed or refractory B-cell non-Hodgkin's lymphoma

  This study is testing a new CAR-T cell therapy to see if it can help people with hard-to-treat B-cell non-Hodgkin's lymphoma feel better and have more treatment options.

  Recruiting at 3 sites Phase 1/2 Chinese PLA General Hospital · Beijing and 2 other locations · NCT06014073

• Evaluating a new treatment for B-Cell Non-Hodgkin's Lymphoma

  This study is testing a new treatment called MBS303 to see if it can help people with relapsed or hard-to-treat B-Cell Non-Hodgkin's Lymphoma feel better and respond well to the therapy.

  Recruiting Phase 1/2 Beijing Mabworks Biotech Co., Ltd. · Beijing · NCT05806099

• GNC-038 injection for patients with relapsed or refractory non-Hodgkin's lymphoma

  This study is testing a new injection treatment called GNC-038 to see if it can help people with relapsed or hard-to-treat non-Hodgkin's lymphoma feel better.

  Recruiting at 3 sites Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT05623982

• CD19-targeting CAR-γδT cell therapy for relapsed non-Hodgkin's lymphoma

  This study is testing a new treatment using special immune cells from healthy donors to see if it can help people with relapsed non-Hodgkin's lymphoma feel better.

  Recruiting at 2 sites Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality and 1 other locations · NCT05554939

• Evaluating the effects of nemtabrutinib in patients with blood cancers

  This study is testing a new oral medication called nemtabrutinib to see if it can help people with blood cancers like chronic lymphocytic leukemia and Waldenström's macroglobulinemia feel better and stay safe.

  Recruiting at 94 sites Phase 2 Merck Sharp & Dohme LLC · Springdale, Arkansas and 120 other locations · NCT04728893

• CD70 CAR T-cell therapy for blood cancers

  This study is testing a new CAR T-cell therapy for blood cancers to see if it is safe and effective for patients with certain types of leukemia and lymphoma.

  Recruiting Early Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT04662294

• Treatment of relapsed or refractory Non-Hodgkin's Lymphoma with CNCT19 Cell Injection

  This study is testing if a single injection of CNCT19 cells can help people with relapsed or refractory Non-Hodgkin's Lymphoma feel better and improve their condition.

  Recruiting at 17 sites Phase 2 Juventas Cell Therapy Ltd. · Beijing, Beijing Municipality and 16 other locations · NCT04586478

• Evaluating APG-115 and APG-2575 for T-Prolymphocytic Leukemia and Non-Hodgkin's Lymphoma

  This study is testing a new treatment using two drugs, APG-115 and APG-2575, to see if they can help people with relapsed or hard-to-treat T-Prolymphocytic Leukemia and Non-Hodgkin's Lymphoma feel better and improve their health.

  Recruiting Phase 2 Ascentage Pharma Group Inc. · Houston, Texas · NCT04496349

• Combining acalabrutinib with standard chemotherapy for untreated aggressive B-cell lymphoma

  This study is testing if adding a new drug called acalabrutinib to standard chemotherapy can help people with untreated aggressive B-cell lymphoma get better results.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04002947

• CLIC-1901 treatment for relapsed/refractory CD19 positive blood cancers

  This study is testing a new treatment called CLIC-1901 for people with hard-to-treat blood cancers to see if it can help them feel better.

  Recruiting at 2 sites Phase 1/2 Ottawa Hospital Research Institute · Vancouver, British Columbia and 2 other locations · NCT03765177

• Registry for collecting data on adult Acute Lymphoblastic Leukemia patients

  This study is collecting information from adults with Acute Lymphoblastic Leukemia to see how well different treatments work and to improve care for future patients.

  Recruiting at 147 sites Goethe University · Graz and 146 other locations · NCT02872987

• Identifying Prognostic Factors in Mycosis Fungoides and Sezary Syndrome

  This study is trying to find out which factors can help predict survival for patients with advanced mycosis fungoides and Sezary syndrome to improve their care and outcomes.

  Recruiting at 13 sites Stanford University · Duarte, California and 12 other locations · NCT02848274

• CD30-targeted CAR T-cell therapy for relapsed and refractory lymphomas

  This study is testing a new treatment using modified T cells to see if it can help people with relapsed or hard-to-treat Hodgkin's and Non-Hodgkin's lymphoma.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT02259556

• Collecting and reporting data on patients receiving stem cell transplants

  This study is trying to gather and share information about patients getting stem cell transplants for blood cancers to better understand how well these treatments work.

  Recruiting Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT01890486

• Using special T cells to treat EBV-positive lymphoma

  This study is testing a new treatment using special T cells to help people with EBV-positive Hodgkin's or non-Hodgkin lymphoma fight their cancer.

  Recruiting at 2 sites Phase 1 Baylor College of Medicine · Houston, Texas and 2 other locations · NCT01555892

• Creating a tumor bank for families with multiple blood cancers

  This study is trying to collect samples from families with multiple blood cancers to see if there are specific genetic factors that make them more likely to develop lymphomas.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT00131014

Related topics

Quick answers

How many Non-Hodgkin's Lymphoma clinical trials are recruiting right now?

23, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in China (13 trials), United States (8 trials), Australia (3 trials), Canada (3 trials), Argentina (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 9, Phase 2: 4, Phase 1: 3, Phase 2/3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →